Investigative Ophthalmology & Visual Science Cover Image for Volume 63, Issue 7
June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Central Serous Chorioretinopathy associated with Ocular Tuberculosis
Author Affiliations & Notes
  • Jila Noorikolouri
    Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
  • Christian Leal
    Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States
  • Footnotes
    Commercial Relationships   Jila Noorikolouri None; Christian Leal None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3217 – A0443. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jila Noorikolouri, Christian Leal; Central Serous Chorioretinopathy associated with Ocular Tuberculosis. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3217 – A0443.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : .To report two cases of central serous chorioretinopathy (CSCR) associated with ocular tuberculosis (TB) and improvement following the standard anti-TB treatment

Methods : The first case was a 61 years-old native of India male who presented with recurrent iridocyclitis and episcleritis of the left eye. Fundus exam and macula Optical Coherence Tomography (OCT) revealed subretinal fluid (SRF) and pigmentary changes in the right eye suggestive for CSCR. The normal CXR and the positive quantiferon gold test indicated presumed ocular TB.
The second case was a 47-year-old Mexican male who presented with occlusive retinal vasculitis of unclear etiology and chronic CSCR in both eyes and positive quantiferon gold test.
Both patients subsequently started anti-TB treatment with a two-month course of moxifloxacin 400mg, rifampin 600mg, isoniazid 300mg, pyrazinamide 1500mg, and vitamin B6 50mg daily. Pyrazinamide was discontinued in the first patient after a week of pruritic rash. Both patients ultimately remained on rifampin 600mg, isoniazid 300mg, and B6 50mg daily for a planned treatment course of 9 months.

Results : First patients showed resolution of SRF in 2 months with no recurrence of either the fluid in the right eye and iridocyclitis and episcleritis of the left eye at subsequent follow-up visits, by the end of 7 months ant-TB treatment.
In the second case, the SRF resolved completely in the right eye in 3 months and the left eye in 5 months without recurrence by the end of ani-TB treatment.

Conclusions : Ocular TB may present as CSCR and improve with the standard anti- TB treatment. Large long-term clinical observations are required to confirm this association and response to the treatment.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Improvement of subretinal fluid following anti-TB treatment- Extrafoveal subretinal fluid (SRF) at the first patient’s first evaluation in uveitis clinic (A). Resolution of SRF and outer retinal atrophy two months after initiation of anti-TB treatment in the right eye (B). SRF in the right eye of the second patient (C). OCT B scan shows resolution of SRF three months after initiation of Anti- TB treatment (D). Extrafoveal SRF in the left eye (E). Complete resolution of sub-foveal fluid in 5 months of anti-TB treatment (F). OCT in both eyes shows other features of CSCR, including thick choroid and atrophic changes of RPE (C-F).

Improvement of subretinal fluid following anti-TB treatment- Extrafoveal subretinal fluid (SRF) at the first patient’s first evaluation in uveitis clinic (A). Resolution of SRF and outer retinal atrophy two months after initiation of anti-TB treatment in the right eye (B). SRF in the right eye of the second patient (C). OCT B scan shows resolution of SRF three months after initiation of Anti- TB treatment (D). Extrafoveal SRF in the left eye (E). Complete resolution of sub-foveal fluid in 5 months of anti-TB treatment (F). OCT in both eyes shows other features of CSCR, including thick choroid and atrophic changes of RPE (C-F).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×